{{Rsnum
|rsid=4769060
|Gene=ALOX5AP
|Chromosome=13
|position=30763740
|Orientation=plus
|GMAF=0.3356
|Gene_s=ALOX5AP
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 26.5 | 49.6 | 23.9
| HCB | 47.4 | 43.1 | 9.5
| JPT | 41.6 | 46.0 | 12.4
| YRI | 91.0 | 9.0 | 0.0
| ASW | 72.7 | 23.6 | 3.6
| CHB | 47.4 | 43.1 | 9.5
| CHD | 54.1 | 39.4 | 6.4
| GIH | 53.5 | 37.6 | 8.9
| LWK | 91.5 | 7.5 | 0.9
| MEX | 29.3 | 37.9 | 32.8
| MKK | 73.1 | 25.0 | 1.9
| TSI | 33.3 | 52.9 | 13.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=24225399
|Title=Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity
}}

{{PMID Auto
|PMID=24368493
|Title=Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese
}}

{{PMID Auto
|PMID=24485247
|Title=Ischemic stroke risk in a southeastern Chinese population: Insights from 5-lipoxygenase activating protein and phosphodiesterase 4D single-nucleotide polymorphisms
}}

{{PMID Auto
|PMID=20592751
|Title=Human lipoxygenase pathway gene variation and association with markers of subclinical atherosclerosis in the diabetes heart study.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}